However, in other cancer types, including melanoma, hepatocellular carcinoma, colorectal carcinoma, endometrial carcinoma, and ccRCC, PD-L1 expression levels are not used to direct treatments with ICIs. This evidence concerns the gene CD274 and hepatocellular carcinoma.